The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL

NCT00441025 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped a lack of a potential patient.

Conditions

Peripheral T-Cell Lymphoma

Interventions

DRUG: Alemtuzumab

Sponsor

Mahidol University

Collaborators

[object Object]